AnaCardio

Description

AnaCardio develops novel inotropic drugs that act via the ghrelin signalling pathway to increase cardiomyocyte contractility and cardiac output, aiming to improve organ function, quality of life, and reduce hospitalization risk in heart failure patients.

AnaCardio is located in the Stockholm ecosystem.

Related

• OncopeptidesOncopeptides develops peptide drug conjugates that use tumor-overexpressed peptidases and esterases to release an alkylating payload…
• Heartbeat BioHeartbeat Bio builds customizable Cardioid heart chamber models from iPSCs and provides assay platforms and disease-specific models for…
• FineHeartFineHeart develops FlowMaker as a therapy for advanced heart failure, creates clinical-stage cardiology technology, and leads an IPCEI…
• CorWaveCorWave develops an implantable left ventricular assist pump that uses a wave membrane to produce truly pulsatile blood flow for treating…
• FIRE1FIRE1 develops NORM, an investigational heart failure management system that combines an implanted sensor in the inferior vena cava with a…
• LUMA VISIONLUMA VISION develops imaging hardware, software and machine-learning systems for interventional cardiac imaging including an…
• OrexoOrexo develops powder-based drug delivery technologies and therapeutic formulations, including AmorphOX®, used to improve bioavailability…
• Qubit PharmaceuticalsQubit Pharmaceuticals develops quantum- and AI-driven molecular modeling platforms and drug discovery tools used to design novel drug…
• Devyser DiagnosticsDevyser Diagnostics develops DNA test kits and integrated software for laboratory DNA diagnostics, helping labs run genetic testing…